Erik Penser Bank has initiated coverage of Hansa Biopharma with a buy recommendation

Read report

Hansa Biopharma reported its H1’21 Earnings on July 15, 2021. Access the report and conference call here

Read report and view webcast

Updated company collected consensus available from 11 banks and research institutions

Read More

First national level reimbursement decision achieved in Sweden end of June 2021

Read more

CEO Søren Tulstrup and Chairman Ulf Wiinberg have increased ownership in Hansa Biopharma

Read More

H.C. Wainwright has initiated coverage of Hansa Biopharma with a buy recommendation

Read report

Three year long-term data has been published in American Journal of Transplantation

Read aricle

ABG Sundal Collier hosted a call KOL expert call Dr. Bengt von Zur-Mühlen on 2021-03-24

View webcast

Hansa Biopharma in brief

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients.

The Company has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer.

Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

Our Equity Story

Imlifidase works
Targeting rare diseases with a high unmet medical need
Addresses a clear unmet need
Commercialize Idefirix® in first markets and indications
Well positioned for commercial success
Evolution into a fully integrated biopharmaceutical company
Rich pipeline
Leveraging our proprietary antibody cleaving enzyme technology

Learn More

Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcomming Events

Milestones and near-term news flow

Near Term News Near Term News

For any investor related inquiries, please contact